Guest guest Posted January 5, 2011 Report Share Posted January 5, 2011 Spectrum Pharmaceuticals Inc. said it will develop a biosimilar version of the cancer drug Rituxan through a new partnership with Viropro Inc. Spectrum makes Zevalin, a CD20 targeted radiotherapy monoclonal sometimes used in CLL. Other versions of rituxan are expected from India and other countries. Source: Bloomberg ~chris Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.